Search - tctmd.com

Displaying 21 - 40 of 162

Sort: Relevancy | Date

News Opinion Editor's Corner

The Biggest News of 2023: TCTMD’s Top 10

Shelley Wood

January 01, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Todd Neale

September 19, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Todd Neale

January 18, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Michael O'Riordan

August 11, 2022

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Todd Neale

April 03, 2022

Advertisement

The Biggest News of 2023: TCTMD’s Top 10

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

LDL Control Remains Poor in CAD Patients: NHANES

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content